Effect of vaccination of pneumococcal infection on the course of chronic obstructive pulmonary disease in combination with diabetes mellitus

Abstract

Objective: to evaluate the effect of conjugated pneumococcal vaccine Prevenar 13 on the course of COPD in combination with type 2 diabetes. The study included 76 patients with COPD III (40.8%) and COPD IV (59.2%) in combination with type 2 diabetes, 72 (94.7%) men and 4 (5.3%) women, averaga age 64.72 years. All patients were current or past smokers, the smoking index- 45.11. The duration of COPD was 8.71 years, the lasting of diabetes mellitus was 10.23 years. All patients were overweight, BMI=31.67 kg/m2. ± Before vaccination, patients reported severe clinical symptoms (CAT=27.99±3.79, CI 95% 19-36) and particularly severe dyspnea (mMRC=2.72±0.53, CI 95% 2-4), frequent exacerbations (3.45±0.85, CI 95% 2-5) episodes per year, in 33 (43.4%) with hospitalization and pneumonia in 17 (22.37%) patients. Three years after the PCV13 vaccination, the number of exacerbations of COPD significantly decreased by 1.47±0.71 (p Thus, PCV13 vaccination of patients with COPD in combanation with diabetes mallitus can improve the course of the disease by reduction the number of exacerbations and decreasing the incidence of pneumonia.